热门资讯> 正文
德尼凡斯塔在后期试验中成功后，萨吉梅特崛起
2025-10-24 21:37
- Sagimet Biosciences (NASDAQ:SGMT) announced positive results from a late-stage trial of denifanstat, a treatment for moderate to severe acne vulgaris, which was conducted by its partner, Ascletis Bioscience, in China.
- The trial successfully achieved all primary and secondary objectives.
- At the 12-week mark, patients treated with denifanstat experienced treatment success rates that were more than double those of the placebo group, showing significant improvements in both inflammatory and non-inflammatory acne lesions.
- Overall, denifanstat was well tolerated by participants. Following the announcement, SGMT stock rose approximately 6.3%.
More on Sagimet Biosciences
- Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts
- Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
- Sagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At Hold
- Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
- MASH drug developers rise as FDA accepts lenient trial requirement
推荐文章
华盛早报 | 美就业疲软提振降息预期，道指创新高；段永平最新表态！重仓三只股票：苹果、腾讯控股、茅台
美股机会日报 | 特斯拉放大招！拟年产1000万台Optimus机器人；美国政府停摆有望于周三结束
资金复盘 | 北水净流入港股近45亿港元，扫货小米近12亿港元，小鹏汽车遭抛售
财报前瞻 | “股王”腾讯放榜在即！高盛、大摩集体唱多，股价700港元根本不是顶？
超5万亿美元！摩根大通：全球AI基建“规模空前”，将影响所有资本市场
谢幕，巴菲特发布最后一封致股东信（全文）
美联储理事米兰继续大放“鸽声” 愿接受12月降息25基点
11月11日外盘头条：巴菲特加快财富捐赠力度 特斯拉10月销量大幅下滑 美航司取消逾1600个航班
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
